Progress in circRNA-Targeted Therapy in Experimental Parkinson's Disease

Area of Science:

• Molecular Biology
• Neuroscience
• Biotechnology

Background:

• Circular RNAs (circRNAs) are increasingly recognized for their role in disease pathogenesis.
• Specific circRNAs, including circSNCA, circHIPK2, circHIPK3, and circSLC8A1, are linked to Parkinson's disease (PD) neurodegeneration.
• Understanding circRNA function is crucial for advancing neurodegenerative disease research.

Purpose of the Study:

• To explore the potential of circRNAs as therapeutic targets for neurodegenerative diseases.
• To review the current methodologies for manipulating circRNA expression.
• To assess the feasibility of translating circRNA-based therapies from research to clinical application.

Main Methods:

• Review of gain-of-function studies using viral/non-viral vectors for circRNA overexpression.
• Analysis of loss-of-function studies employing CRISPR/Cas, antisense oligonucleotides (ASOs), and RNA interference (RNAi).
• Examination of challenges and opportunities in developing oligonucleotide-based brain delivery systems.

Main Results:

• Gain-of-function and loss-of-function studies elucidate the pathobiology of circRNAs in disease.
• Aberrant circRNA expression in brain pathology highlights their potential as therapeutic targets.
• Progress in RNAi-based therapies and significant pharmaceutical investment underscore the potential of circRNAs.

Conclusions:

• CircRNAs represent a significant opportunity for developing novel oligonucleotide-based therapies.
• Targeting circRNAs could offer a strategy to slow or halt the progression of neurodegenerative diseases.
• Overcoming challenges in delivery and cost is key to realizing the therapeutic potential of circRNAs.